{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T02:28:49Z","timestamp":1787711329544,"version":"build-2784847793"},"reference-count":74,"publisher":"The Endocrine Society","issue":"9","license":[{"start":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T00:00:00Z","timestamp":1678752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Polycystic ovary syndrome (PCOS) is a common endocrine disorder associated with low-grade systemic inflammation and increased risk of pregnancy complications. Metformin treatment reduces the risk of late miscarriage and preterm birth in pregnant women with PCOS. Whether the protective effect of metformin involves immunological changes has not been determined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the effect of metformin on the maternal immunological status in women with PCOS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A post-hoc analysis was performed of two randomized controlled trials, PregMet and PregMet2, including longitudinal maternal serum samples from 615 women with PCOS. Women were randomized to metformin or placebo from first trimester to delivery. Twenty-two cytokines and C-reactive protein were measured in serum sampled at gestational weeks 5 to 12, 19, 32, and 36.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Metformin treatment was associated with higher serum levels of several multifunctional cytokines throughout pregnancy, with the strongest effect on eotaxin (P &amp;lt; .001), interleukin-17 (P = .03), and basic fibroblast growth factor (P = .04). Assessment of the combined cytokine development confirmed the impact of metformin on half of the 22 cytokines. The immunomodulating effect of metformin was more potent in normal weight and overweight women than in obese women. Moreover, normoandrogenic women had the strongest effect of metformin in early pregnancy, whereas hyperandrogenic women presented increasing effect throughout pregnancy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>It appears that metformin has immunomodulating rather than anti-inflammatory properties in pregnancy. Its effect on the serum levels of many multifunctional cytokines demonstrates robust, persisting, and body mass\u2013dependent immune mobilization in pregnant women with PCOS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgad145","type":"journal-article","created":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T09:46:21Z","timestamp":1678787181000},"page":"e743-e753","source":"Crossref","is-referenced-by-count":18,"title":["Immunomodulatory Effects of Metformin Treatment in Pregnant Women With PCOS"],"prefix":"10.1210","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4961-214X","authenticated-orcid":false,"given":"Mariell","family":"Ryssdal","sequence":"first","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU) , 7491 Trondheim , Norway"},{"name":"Centre of Molecular Inflammation Research (CEMIR), Norwegian University of Science and Technology , 7491 Trondheim , Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eszter","family":"Vanky","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU) , 7491 Trondheim , Norway"},{"name":"Department of Obstetrics and Gynecology, St. Olavs Hospital, Trondheim University Hospital , 7006 Trondheim , Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2647-4947","authenticated-orcid":false,"given":"Live Marie T","family":"Stokkeland","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU) , 7491 Trondheim , Norway"},{"name":"Centre of Molecular Inflammation Research (CEMIR), Norwegian University of Science and Technology , 7491 Trondheim , Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders Hagen","family":"Jarmund","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU) , 7491 Trondheim , Norway"},{"name":"Centre of Molecular Inflammation Research (CEMIR), Norwegian University of Science and Technology , 7491 Trondheim , Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f8rg","family":"Steinkjer","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU) , 7491 Trondheim , Norway"},{"name":"Centre of Molecular Inflammation Research (CEMIR), Norwegian University of Science and Technology , 7491 Trondheim , Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tone Shetelig","family":"L\u00f8vvik","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU) , 7491 Trondheim , Norway"},{"name":"Department of Obstetrics and Gynecology, St. Olavs Hospital, Trondheim University Hospital , 7006 Trondheim , Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torfinn St\u00f8ve","family":"Madssen","sequence":"additional","affiliation":[{"name":"Department of Circulation and Medical Imaging, Norwegian University of Science and Technology , 7491 Trondheim , Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Charlotte","family":"Iversen","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU) , 7491 Trondheim , Norway"},{"name":"Centre of Molecular Inflammation Research (CEMIR), Norwegian University of Science and Technology , 7491 Trondheim , Norway"},{"name":"Department of Obstetrics and Gynecology, St. Olavs Hospital, Trondheim University Hospital , 7006 Trondheim , Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guro F","family":"Giske\u00f8deg\u00e5rd","sequence":"additional","affiliation":[{"name":"K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Norwegian University of Science and Technology , 7491 Trondheim , Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2023,3,14]]},"reference":[{"issue":"5","key":"2023081819570387200_dgad145-B1","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/j.fertnstert.2010.09.032","article-title":"Polycystic ovary syndrome: an ancient disorder?","volume":"95","author":"Azziz","year":"2011","journal-title":"Fertil Steril"},{"issue":"12","key":"2023081819570387200_dgad145-B2","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1093\/humrep\/dew218","article-title":"The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis","volume":"31","author":"Bozdag","year":"2016","journal-title":"Hum Reprod"},{"issue":"1","key":"2023081819570387200_dgad145-B3","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.fertnstert.2016.05.003","article-title":"Criteria, prevalence, and phenotypes of polycystic ovary syndrome","volume":"106","author":"Lizneva","year":"2016","journal-title":"Fertil Steril"},{"issue":"5","key":"2023081819570387200_dgad145-B4","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1210\/er.2015-1104","article-title":"The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited","volume":"37","author":"Rosenfield","year":"2016","journal-title":"Endocr Rev"},{"key":"2023081819570387200_dgad145-B5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jsbmb.2018.04.008","article-title":"Polycystic ovary syndrome (PCOS), an inflammatory, systemic, lifestyle endocrinopathy","volume":"182","author":"Patel","year":"2018","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2023081819570387200_dgad145-B6","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.cca.2019.11.003","article-title":"Polycystic ovarian syndrome: correlation between hyperandrogenism, insulin resistance and obesity","volume":"502","author":"Zeng","year":"2020","journal-title":"Clin Chim Acta"},{"issue":"6","key":"2023081819570387200_dgad145-B7","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1210\/er.2011-1034","article-title":"Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications","volume":"33","author":"Diamanti-Kandarakis","year":"2012","journal-title":"Endocr Rev"},{"issue":"3","key":"2023081819570387200_dgad145-B8","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.fertnstert.2010.11.036","article-title":"Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis","volume":"95","author":"Escobar-Morreale","year":"2011","journal-title":"Fertil Steril"},{"issue":"1","key":"2023081819570387200_dgad145-B9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.fertnstert.2011.11.023","article-title":"Is PCOS an inflammatory process?","volume":"97","author":"Duleba","year":"2012","journal-title":"Fertil Steril"},{"issue":"3","key":"2023081819570387200_dgad145-B10","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1055\/s-0037-1603096","article-title":"Polycystic ovarian syndrome: long-term health consequences","volume":"35","author":"Zore","year":"2017","journal-title":"Semin Reprod Med"},{"issue":"1","key":"2023081819570387200_dgad145-B11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.fertnstert.2003.10.004","article-title":"Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome","volume":"81","author":"Rotterdam ESHRE\/ASRM-sponsored PCOS consensus workshop group","year":"2004","journal-title":"Fertil Steril"},{"issue":"1","key":"2023081819570387200_dgad145-B12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1742-4755-12-7","article-title":"A case-control observational study of insulin resistance and metabolic syndrome among the four phenotypes of polycystic ovary syndrome based on Rotterdam criteria","volume":"12","author":"Jamil","year":"2015","journal-title":"Reprod Health"},{"issue":"4","key":"2023081819570387200_dgad145-B13","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1089\/jwh.2014.5000","article-title":"Prevalence of infertility and use of fertility treatment in women with polycystic ovary syndrome: data from a large community-based cohort study","volume":"24","author":"Joham","year":"2015","journal-title":"J Womens Health (Larchmt)"},{"issue":"7","key":"2023081819570387200_dgad145-B14","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1093\/humrep\/deaa099","article-title":"Polycystic ovary syndrome as an independent risk factor for gestational diabetes and hypertensive disorders of pregnancy: a population-based study on 9.1 million pregnancies","volume":"35","author":"Mills","year":"2020","journal-title":"Hum Reprod"},{"issue":"51","key":"2023081819570387200_dgad145-B15","doi-asserted-by":"crossref","first-page":"e4863","DOI":"10.1097\/MD.0000000000004863","article-title":"Association between polycystic ovary syndrome and the risk of pregnancy complications: a PRISMA-compliant systematic review and meta-analysis","volume":"95","author":"Yu","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"8","key":"2023081819570387200_dgad145-B16","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nri.2017.64","article-title":"The unique immunological and microbial aspects of pregnancy","volume":"17","author":"Mor","year":"2017","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"2023081819570387200_dgad145-B17","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1600-0897.2010.00836.x","article-title":"The immune system in pregnancy: a unique complexity","volume":"63","author":"Mor","year":"2010","journal-title":"Am J Reprod Immunol"},{"key":"2023081819570387200_dgad145-B18","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6649608","article-title":"Maternal serum cytokine concentrations in healthy pregnancy and preeclampsia","volume":"2021","author":"Spence","year":"2021","journal-title":"J Pregnancy"},{"issue":"1","key":"2023081819570387200_dgad145-B19","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1471-2172-11-59","article-title":"Circulating cytokines, chemokines and adhesion molecules in normal pregnancy and preeclampsia determined by multiplex suspension array","volume":"11","author":"Szarka","year":"2010","journal-title":"BMC Immunol"},{"issue":"7","key":"2023081819570387200_dgad145-B20","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.2337\/dc12-1934","article-title":"Serum inflammatory markers and preeclampsia in type 1 diabetes: a prospective study","volume":"36","author":"Du","year":"2013","journal-title":"Diabetes Care"},{"issue":"4","key":"2023081819570387200_dgad145-B21","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/biolre\/ioaa102","article-title":"The role of the IL-1 system in pregnancy and the use of IL-1 system markers to identify women at risk for pregnancy complications","volume":"103","author":"Equils","year":"2020","journal-title":"Biol Reprod"},{"issue":"8","key":"2023081819570387200_dgad145-B22","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1210\/jc.2014-1214","article-title":"Low-grade chronic inflammation in pregnant women with polycystic ovary syndrome: a prospective controlled clinical study","volume":"99","author":"Palomba","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023081819570387200_dgad145-B23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1210\/clinem\/dgab684","article-title":"Changes in serum cytokines throughout pregnancy in women with polycystic ovary syndrome","volume":"107","author":"Stokkeland","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"suppl 1","key":"2023081819570387200_dgad145-B24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2165\/00003495-199958001-00009","article-title":"The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms","volume":"58","author":"Wiernsperger","year":"1999","journal-title":"Drugs"},{"issue":"1","key":"2023081819570387200_dgad145-B25","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/1472-6874-14-93","article-title":"Effect of metformin on serum interleukin-6 levels in polycystic ovary syndrome: a systematic review","volume":"14","author":"Xu","year":"2014","journal-title":"BMC Women's Health"},{"issue":"3","key":"2023081819570387200_dgad145-B26","doi-asserted-by":"crossref","first-page":"196","DOI":"10.2174\/1871530315666150316124019","article-title":"Metformin and inflammation: its potential beyond glucose-lowering effect","volume":"15","author":"Saisho","year":"2015","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"5","key":"2023081819570387200_dgad145-B27","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1161\/CIRCRESAHA.116.308445","article-title":"Anti-inflammatory effects of metformin irrespective of diabetes status","volume":"119","author":"Cameron","year":"2016","journal-title":"Circ Res"},{"issue":"12","key":"2023081819570387200_dgad145-B28","article-title":"Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility","volume":"12","author":"Morley","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"7421","key":"2023081819570387200_dgad145-B29","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1136\/bmj.327.7421.951","article-title":"Metformin in polycystic ovary syndrome: systematic review and meta-analysis","volume":"327","author":"Lord","year":"2003","journal-title":"BMJ"},{"issue":"3","key":"2023081819570387200_dgad145-B30","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.fertnstert.2017.06.026","article-title":"Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline","volume":"108","author":"Practice Committee of the American Society for Reproductive Medicine","year":"2017","journal-title":"Fertil Steril"},{"issue":"1","key":"2023081819570387200_dgad145-B31","first-page":"139","article-title":"Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation","volume":"85","author":"Moghetti","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2023081819570387200_dgad145-B32","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/humupd\/dmv025","article-title":"Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis","volume":"21","author":"Naderpoor","year":"2015","journal-title":"Hum Reprod Update"},{"issue":"10","key":"2023081819570387200_dgad145-B33","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/s41574-018-0081-6","article-title":"Metformin in pregnancy - safe or sorry?","volume":"14","author":"Vanky","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"2023081819570387200_dgad145-B34","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.fertnstert.2006.02.098","article-title":"Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis","volume":"86","author":"Gilbert","year":"2006","journal-title":"Fertil Steril"},{"issue":"9","key":"2023081819570387200_dgad145-B35","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1007\/s00125-017-4351-y","article-title":"Metformin use in pregnancy: promises and uncertainties","volume":"60","author":"Lindsay","year":"2017","journal-title":"Diabetologia"},{"key":"2023081819570387200_dgad145-B36","doi-asserted-by":"crossref","first-page":"k2477","DOI":"10.1136\/bmj.k2477","article-title":"Metformin exposure in first trimester of pregnancy and risk of all or specific congenital anomalies: exploratory case-control study","volume":"361","author":"Given","year":"2018","journal-title":"BMJ"},{"issue":"3","key":"2023081819570387200_dgad145-B37","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/S2352-4642(18)30385-7","article-title":"Intrauterine metformin exposure and offspring cardiometabolic risk factors (PedMet study): a 5-10 year follow-up of the PregMet randomised controlled trial","volume":"3","author":"Hanem","year":"2019","journal-title":"Lancet Child Adolesc Health"},{"issue":"4","key":"2023081819570387200_dgad145-B38","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S2213-8587(19)30002-6","article-title":"Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): a randomised, double-blind, placebo-controlled trial","volume":"7","author":"L\u00f8vvik","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2023081819570387200_dgad145-B39","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.cyto.2019.03.013","article-title":"Serum cytokine patterns in first half of pregnancy","volume":"119","author":"Stokkeland","year":"2019","journal-title":"Cytokine"},{"key":"2023081819570387200_dgad145-B40","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.752660","article-title":"Cytokine patterns in maternal serum from first trimester to term and beyond","volume":"12","author":"Jarmund","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"2023081819570387200_dgad145-B41","doi-asserted-by":"crossref","first-page":"17819","DOI":"10.1038\/s41598-020-74722-5","article-title":"Longitudinal plasma inflammatory proteome profiling during pregnancy in the born into life study","volume":"10","author":"Hedman","year":"2020","journal-title":"Sci Rep"},{"issue":"5","key":"2023081819570387200_dgad145-B42","doi-asserted-by":"crossref","DOI":"10.1111\/aji.13531","article-title":"Longitudinal changes in serum immune markers during normal pregnancy in a North-Indian population","volume":"87","author":"Kaushal","year":"2022","journal-title":"Am J Reprod Immunol"},{"issue":"11","key":"2023081819570387200_dgad145-B43","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1161\/ATVBAHA.115.305817","article-title":"Distinct first trimester cytokine profiles for gestational hypertension and preeclampsia","volume":"35","author":"Tanger\u00e5s","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"2023081819570387200_dgad145-B44","doi-asserted-by":"crossref","DOI":"10.1111\/aji.12818","article-title":"Multivariate analysis of cytokine profiles in pregnancy complications","volume":"79","author":"Azizieh","year":"2018","journal-title":"Am J Reprod Immunol"},{"issue":"12","key":"2023081819570387200_dgad145-B45","doi-asserted-by":"crossref","first-page":"E448","DOI":"10.1210\/jc.2010-0853","article-title":"Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: a randomized, controlled multicenter study","volume":"95","author":"Vanky","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2023081819570387200_dgad145-B46","author":"Ryssdal"},{"key":"2023081819570387200_dgad145-B47","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.chemolab.2015.02.019","article-title":"Zcompositions\u2014R package for multivariate imputation of left-censored data under a compositional approach","volume":"143","author":"Palarea-Albaladejo","year":"2015","journal-title":"Chemom Intell Lab Syst"},{"key":"2023081819570387200_dgad145-B48","author":"World Health Organization"},{"issue":"1","key":"2023081819570387200_dgad145-B49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v067.i01","article-title":"Fitting linear mixed-effects models using lme4","volume":"67","author":"Bates","year":"2015","journal-title":"J Stat Soft"},{"key":"2023081819570387200_dgad145-B50","doi-asserted-by":"crossref","first-page":"e5840","DOI":"10.1136\/bmj.e5840","article-title":"Reporting and analysis of trials using stratified randomisation in leading medical journals: review and reanalysis","volume":"345","author":"Kahan","year":"2012","journal-title":"BMJ"},{"key":"2023081819570387200_dgad145-B51","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.conctc.2018.03.008","article-title":"Different ways to estimate treatment effects in randomised controlled trials","volume":"10","author":"Twisk","year":"2018","journal-title":"Contemp Clin Trials Commun"},{"issue":"1","key":"2023081819570387200_dgad145-B52","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc Ser B (Methodological)"},{"issue":"11","key":"2023081819570387200_dgad145-B53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1009585","article-title":"Repeated measures ASCA+ for analysis of longitudinal intervention studies with multivariate outcome data","volume":"17","author":"Madssen","year":"2021","journal-title":"PLoS Comput Biol"},{"key":"2023081819570387200_dgad145-B54","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.962431","article-title":"ALASCA: an R package for longitudinal and cross-sectional analysis of multivariate data by ASCA-based methods","volume":"9","author":"Jarmund","year":"2022","journal-title":"Front Mol Biosci"},{"issue":"10","key":"2023081819570387200_dgad145-B55","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S2213-8587(15)00219-3","article-title":"Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial","volume":"3","author":"Chiswick","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"2023081819570387200_dgad145-B56","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1210\/jc.2008-0461","article-title":"The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials","volume":"93","author":"Hoeger","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2023081819570387200_dgad145-B57","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1001\/jama.2009.1347","article-title":"Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial","volume":"302","author":"Pradhan","year":"2009","journal-title":"JAMA"},{"issue":"2","key":"2023081819570387200_dgad145-B58","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ijcard.2008.04.010","article-title":"Metformin inhibits TNF-alpha-induced I\u03baB kinase phosphorylation, I\u03baB-alpha degradation and IL-6 production in endothelial cells through PI3K-dependent AMPK phosphorylation","volume":"134","author":"Huang","year":"2009","journal-title":"Int J Cardiol"},{"issue":"4","key":"2023081819570387200_dgad145-B59","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1210\/clinem\/dgaa951","article-title":"TLR4-associated IRF-7 and NF\u03baB signaling act as a molecular link between androgen and metformin activities and cytokine synthesis in the PCOS endometrium","volume":"106","author":"Hu","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2023081819570387200_dgad145-B60","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155223","article-title":"Metformin: is it a drug for all reasons and diseases?","volume":"133","author":"Triggle","year":"2022","journal-title":"Metabolism"},{"issue":"1","key":"2023081819570387200_dgad145-B61","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1196\/annals.1290.016","article-title":"Maternal and fetal hypothalamic-pituitary-adrenal axes during pregnancy and postpartum","volume":"997","author":"Mastorakos","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"2023081819570387200_dgad145-B62","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/967629","article-title":"The Th1:th2 dichotomy of pregnancy and preterm labour","volume":"2012","author":"Sykes","year":"2012","journal-title":"Mediators Inflamm"},{"key":"2023081819570387200_dgad145-B63","volume-title":"UpToDate","author":"Robinson","year":"2022"},{"issue":"6","key":"2023081819570387200_dgad145-B64","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1600-0897.2010.00852.x","article-title":"Th1\/Th2\/Th17 and regulatory T-cell paradigm in pregnancy","volume":"63","author":"Saito","year":"2010","journal-title":"Am J Reprod Immunol"},{"issue":"4","key":"2023081819570387200_dgad145-B65","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1600-0897.2009.00693.x","article-title":"Interleukin-17 increased progesterone secretion by JEG-3 human choriocarcinoma cells","volume":"61","author":"Pongcharoen","year":"2009","journal-title":"Am J Reprod Immunol"},{"key":"2023081819570387200_dgad145-B66","first-page":"431","volume-title":"Eosinophils in Health and Disease.","author":"Gelfand","year":"2013"},{"issue":"4","key":"2023081819570387200_dgad145-B67","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nri2735","article-title":"How are Th2-type immune responses initiated and amplified?","volume":"10","author":"Paul","year":"2010","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"2023081819570387200_dgad145-B68","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ydbio.2005.09.011","article-title":"Functions and regulations of fibroblast growth factor signaling during embryonic development","volume":"287","author":"Thisse","year":"2005","journal-title":"Dev Biol"},{"issue":"4","key":"2023081819570387200_dgad145-B69","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1095\/biolreprod64.4.1033","article-title":"Angiogenesis in the placenta1","volume":"64","author":"Reynolds","year":"2001","journal-title":"Biol Reprod"},{"issue":"8","key":"2023081819570387200_dgad145-B70","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/jog.14335","article-title":"Role of basic fibroblast growth factor in human immunodeficiency virus associated pre-eclampsia","volume":"46","author":"Sangany","year":"2020","journal-title":"J Obstet Gynaecol Res"},{"issue":"11","key":"2023081819570387200_dgad145-B71","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1080\/14767050802251024","article-title":"Placental expression of insulin-like growth factor-I, fibroblast growth factor-basic, and neural cell adhesion molecule in preeclampsia","volume":"21","author":"\u00d6zkan","year":"2008","journal-title":"J Matern Fetal Neonatal Med"},{"key":"2023081819570387200_dgad145-B72","doi-asserted-by":"crossref","first-page":"n2103","DOI":"10.1136\/bmj.n2103","article-title":"Use of metformin to prolong gestation in preterm pre-eclampsia: randomised, double blind, placebo controlled trial","volume":"374","author":"Cluver","year":"2021","journal-title":"BMJ"},{"issue":"15","key":"2023081819570387200_dgad145-B73","first-page":"8136","article-title":"Metformin doses and body mass index: clinical outcomes in insulin resistant polycystic ovary syndrome women","volume":"24","author":"Morgante","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"1","key":"2023081819570387200_dgad145-B74","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1152\/physrev.00033.2011","article-title":"Pathophysiology of human visceral obesity: an update","volume":"93","author":"Tchernof","year":"2013","journal-title":"Physiol Rev"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgad145\/49748677\/dgad145.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/9\/e743\/51172151\/dgad145.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/9\/e743\/51172151\/dgad145.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T06:31:58Z","timestamp":1729060318000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/108\/9\/e743\/7077195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,14]]},"references-count":74,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,3,14]]},"published-print":{"date-parts":[[2023,8,18]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgad145","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9]]},"published":{"date-parts":[[2023,3,14]]}}}